GIKLY - Grifols, S.A.
| Previous Close | 14.90 |
| Open | 14.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 14.90 - 14.90 |
| 52 Week Range | 12.60 - 16.21 |
| Volume | 1 |
| Avg. Volume | 64 |
| Market Cap | 17.917B |
| Beta (3Y Monthly) | 0.70 |
| PE Ratio (TTM) | 24.85 |
| EPS (TTM) | 0.60 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.16 (1.10%) |
| Ex-Dividend Date | 2019-06-07 |
| 1y Target Est | N/A |
- Simply Wall St.
Is Grifols, S.A.'s (BME:GRF) ROE Of 12% Impressive?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Grifols SA (GRFS)
We can judge whether Grifols SA (NASDAQ:GRFS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]
- Simply Wall St.
Is Grifols, S.A. (BME:GRF) Worth €27.10 Based On Its Intrinsic Value?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Grifols, S.A...
- Simply Wall St.
Should Grifols (BME:GRF) Be Disappointed With Their 61% Profit?
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...
- Simply Wall St.
Is Grifols, S.A.'s (BME:GRF) 1.2% Dividend Worth Your Time?
Is Grifols, S.A. (BME:GRF) a good dividend stock? How can we tell? Dividend paying companies with growing earnings can...
- PR Newswire
Grifols presents additional encouraging Alzheimer's trial results at AAIC
BARCELONA, Spain, July 16, 2019 /PRNewswire/ -- The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's at the Alzheimer's Association International Conference (AAIC) 2019 in Los Angeles (USA).
- Simply Wall St.
How Much Are Grifols, S.A. (BME:GRF) Insiders Spending On Buying Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- Investor's Business Daily
This Pharma Stock Dodged A Broad Slide For Drugmakers — Here's Why
Shares of Grifols popped in massive volume Friday after the Spain-based pharmaceutical company gained Food and Drug Administration approval for an immunodeficiency treatment.
- Benzinga
The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...
- PR Newswire
Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa
BARCELONA, Spain, July 3, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb, a provider of hemodialysis solutions headquartered in Morocco, as the main supplier for a new manufacturing plant in northern Africa. Grifols will develop, build and automate the main process equipment for the IV solutions line. Grifols Engineering, which provides technology and consultancy services to the pharmaceutical and biotech sectors, will design a state-of-the-art manufacturing line that will produce intravenous solutions bags. This is the first industrial project for Grifols on the African continent.
- PR Newswire
Grifols to launch plasma-protein-based bleeding-control solutions
BARCELONA, Spain, June 19, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL™ fibrin sealant will be the first product it will introduce with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Grifols developed VISTASEAL™, which combines two plasma proteins, fibrinogen and thrombin, and is administered with Ethicon's airless spray device technology.
- Motley Fool
Is Rigel Pharmaceuticals a Buy?
The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?
- Simply Wall St.
Do Institutions Own Grifols, S.A. (BME:GRF) Shares?
Every investor in Grifols, S.A. (BME:GRF) should be aware of the most powerful shareholder groups. Insiders often own...
- Moody's
Grifols World Wide Operations USA, Inc. -- Moody's announces completion of a periodic review of ratings of Grifols S.A.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Grifols S.A. Paris, May 16, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Grifols S.A. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Motley FoolRigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript
RIGL earnings call for the period ending March 31, 2019.
- PR Newswire
Grifols Announces PharmacyKeeper Bidirectional Integration with Epic
BARCELONA, Spain, April 30, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, announced today that its PharmacyKeeper Verification IV Workflow Management system now supports bidirectional integration with Epic.
- PR Newswire
Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia
Investing $1.6 million into local community; set to employ over 40 people from the local area HINESVILLE, Ga. , April 29, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...
- Simply Wall St.
What Does Grifols, S.A.'s (BME:GRF) P/E Ratio Tell You?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how Grifols, S.A.'s (BME:GRF) P/E ratio could help you assess the value on offer...
- PR Newswire
Grifols US donor centers exceed 250,000 pounds of food collected
- About 20% of children in the U.S. are frequently hungry while nearly 50 million Americans do not get enough to eat. RALEIGH, N.C., April 18, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its U.S. network of over 220 donor centers collaborated with local food banks and pantries to collect more than 250,000 pounds of groceries to help address food insecurity in local communities. According to Feeding America, a leading national hunger non-profit, the 253,000 pounds of food collected translates into 211,000i meals to help support the over 50,000 familiesii that cannot put sufficient food on the table.
- PR Newswire
Grifols donations of blood clotting factor helping people with hemophilia globally
- The company has donated more than 100 million international units (IUs) of blood clotting factor medicines globally during multi-year commitment to the WFH in developing regions. - Grifols creates Grifols Humanitarian Awards in Hemophilia to strengthen the global fight against the disease. BARCELONA, Spain, April 15, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing regions has surpassed 100 million international units (IUs) in donated blood clotting factor, a protein in blood that controls bleeding.
- PR Newswire
Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019
BARCELONA, Spain , April 5, 2019 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United ...
- Simply Wall St.
Grifols, S.A. (BME:GRF): What We Can Expect From This Growth Stock
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Grifols, S.A.'s (BME:GRF) earnings update in December 2018, the cons...
- PR Newswire
Grifols Announces the Opening of its new Plasma Donor Center in Russellville, AR
Investing $1.8 million into local community; set to employ over 40 people from the local area RUSSELLVILLE, Ark. , March 23, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...
- Reuters
Spain's Grifols, China's Shanghai RAAS form strategic alliance
Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China. Under the agreement, the Catalan company will take a 26.2 percent stake in Shanghai RAAS in exchange for a stake of 45 percent (with 40 percent voting rights) in its U.S. division Grifols Diagnostic Solutions (GDS). Grifols said that no external financing was required to fund the transaction which is expected to close in the second half of 2019 pending regulatory approval.
